The main purpose of this trial is to determine safety of a gene therapy strategy for the treatment of locally relapsed prostate cancer.
The therapy is based on the injection into the prostate of a viral vector (AdNRGM) carrying a gene called GMCSF which is able to induce a strong immune response against the prostate cancer, and a gene called NTR which is able to convert an inactive ‘pro-drug’ called CB1954 to a powerful anti-cancer drug.
Two days after the injection of the viral vector, the prodrug CB1954 will be administered intravenously. It is expected that the combination of the two drugs acting within the cancer will result in the death of a significant number of cancer cells.
||Dr Prashant Patel
||University of Birmingham
||Medical Research Council, Department of Health & Experimental Cancer Medicine Centre Network
||Locally Relapsed Prostate
||Clinical Trial of an Investigational Medical Product
|UKCRN Study ID: (if applicable)
|Open to new sites?
|Recruitment start date:
|Recruitment end date
|CRCTU Trial Management Team:
||Early Drug Development Team
|Trial E-mail Address: